Patents by Inventor Benjamin Deverman

Benjamin Deverman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240384299
    Abstract: An engineered AAV capsid is provided, in which at least one protein on the capsid is modified to include a n-mer motif, which promotes transduction of the capsid into the central nervous system (CNS). Further embodiments provide a vector system comprising one or more vectors encoding AAV capsids and a method of delivering cargo to the CNS. The method comprises administering, in vivo or in vitro, a AAV capsid according to embodiments described herein and the AVV capsid comprises one or more cargo molecules.
    Type: Application
    Filed: August 1, 2024
    Publication date: November 21, 2024
    Inventors: Benjamin Deverman, Ken Chan
  • Publication number: 20240325568
    Abstract: Highly selective targeting moieties and compositions comprising the targeting moieties are described herein to efficiently transduce endothelial cell of the central nervous system vasculature. Embodiments include use and delivery of the targeting moieties and compositions to selectively direct delivery of cargo.
    Type: Application
    Filed: July 20, 2022
    Publication date: October 3, 2024
    Inventors: Benjamin Deverman, Qin Huang, Ken Chan
  • Publication number: 20220220502
    Abstract: Provided are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain and the liver. Therapeutic and bio-medical research applications of the rAAVs are also described, including without limitation methods of discovering rAAVs using a multiplexed Cre recombination-based AAV targeted evolution (M-CREATE) method, and methods of treating various diseases and conditions by rAAV-mediated transgene therapy.
    Type: Application
    Filed: April 10, 2020
    Publication date: July 14, 2022
    Inventors: Viviana Gradinaru, Sripriya Ravindra Kumar, Benjamin Deverman